NF‐κB signaling in inflammation and cancer

T Zhang, C Ma, Z Zhang, H Zhang, H Hu - MedComm, 2021 - Wiley Online Library
Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered
in 1986, extraordinary efforts have been made to understand the function and regulating …

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Determining cell type abundance and expression from bulk tissues with digital cytometry

AM Newman, CB Steen, CL Liu, AJ Gentles… - Nature …, 2019 - nature.com
Single-cell RNA-sequencing has emerged as a powerful technique for characterizing
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …

Deubiquitinases in cancer

G Dewson, PJA Eichhorn, D Komander - Nature Reviews Cancer, 2023 - nature.com
Ubiquitination is an essential regulator of most, if not all, signalling pathways, and defects in
cellular signalling are central to cancer initiation, progression and, eventually, metastasis …

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma

E Bal, R Kumar, M Hadigol, AB Holmes, LK Hilton… - Nature, 2022 - nature.com
Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma
and remains incurable in around 40% of patients. Efforts to sequence the coding genome …

Role of Bruton's tyrosine kinase in B cells and malignancies

S Pal Singh, F Dammeijer, RW Hendriks - Molecular cancer, 2018 - Springer
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Diffuse large B-cell lymphoma

S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

MJ Alvarez, Y Shen, FM Giorgi, A Lachmann, BB Ding… - Nature …, 2016 - nature.com
Identifying the multiple dysregulated oncoproteins that contribute to tumorigenesis in a given
patient is crucial for develo** personalized treatment plans. However, accurate inference …

Microbiota in pancreatic health and disease: the next frontier in microbiome research

RM Thomas, C Jobin - Nature Reviews Gastroenterology & Hepatology, 2020 - nature.com
Diseases intrinsic to the pancreas such as pancreatitis, pancreatic cancer and type 1
diabetes mellitus impart substantial health and financial burdens on society but identification …

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

WH Wilson, RM Young, R Schmitz, Y Yang… - Nature medicine, 2015 - nature.com
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like
(ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC …